Panvirox - Cellics Therapeutics
Alternative Names: CTI-112Latest Information Update: 31 Mar 2025
At a glance
- Originator Cellics Therapeutics
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Viral infections
Most Recent Events
- 09 Dec 2024 Preclinical trials in Viral infections in USA (unspecified route) prior to December 2024 (Cellics Therapeutics Pipeline, December 2024)